|
|
||
|
Kosan Biosciences
Download PDF Members: Kosan Biosciences is an established cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. Kosan has built an industry-leading position in Hsp90 inhibitors. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's drug candidates have demonstrated the potential to overcome resistance after relapse and to synergize the initial activity of existing cancer therapies. Kosan's first and second generation Hsp90 inhibitor clinical programs have demonstrated antitumor activity in multiple indications. Tanespimycin (KOS-953) is a first generation geldanamycin analog prepared in Kosan's proprietary formulation. The agent is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma and HER2-positive breast cancer. In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin hydrochloride (KOS-1022) are being evaluated in Phase 1 clinical trials. Kosan's epothilone drug candidates have the potential to achieve best-in-class status. Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most widely used classes of chemotherapeutic agents. Kosan's compounds have been specially engineered to overcome resistance to taxanes and to have an attractive clinical profile. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. In February 2007, Roche and Kosan announced the selection of KOS-1584 to advance into a Phase 2 clinical development program in multiple solid tumor types. As a result, the companies have decided to discontinue development of KOS-862 and focus resources on advancing KOS-1584. Kosan has demonstrated a strong track record of achievement and productivity. Today, Kosan has four clinical candidates generating positive anticancer activity and an early-stage cancer pipeline that is advancing toward the clinic. The company is well-capitalized and has built a strong proprietary position. Kosan has demonstrated the ability to establish and maintain strong validating partnerships and has numerous additional assets for partnering. Kosan has two cooperative research and development agreements (CRADAs) with the National Cancer Institute for development of Hsp90 inhibitors. Kosan has a broad development and commercialization collaboration with Roche for the company’s epothilone program, and a worldwide licensing agreement with Pfizer for the company’s motilin agonist program. Kosan was founded in 1995 and is headquartered in Hayward, California. The company currently has approximately 80 employees.
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 31 individuals from Kosan Biosciences using this service.
This page has been viewed 341 times since April 2007, the link to the organisation's website has been followed 53 times Recent Search Terms used to find this page: kosan publications | t | www.kosan.com | kosan.com | Calibre KOSAN | hypothemycin pdf genes | discodermolide news 2008 | Kosan biosciences acquisition roche | kosan discodermolide | kosan discodermolide | . Search for more companies in Hayward Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Kosan Biosciences | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
| Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
